Page last updated: 2024-11-06

bicyclo(3.1.0)hexane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Bicyclo(3.1.0)hexane, also known as norbornane, is a bicyclic hydrocarbon with a rigid, three-dimensional structure. It is a common building block in organic synthesis and has been studied extensively due to its unique properties. Synthesis: Norbornane can be synthesized via the Diels-Alder reaction between cyclopentadiene and ethylene. It is a versatile intermediate in organic synthesis and has been used in the preparation of a wide variety of natural products and pharmaceutical compounds. Effects: Due to its rigid structure, norbornane exhibits unique conformational properties that affect its reactivity and physical properties. It has been used in the development of novel materials with enhanced mechanical strength and thermal stability. Importance: Norbornane has a significant role in organic chemistry and materials science. It is a valuable building block for the synthesis of complex molecules and has been used in the development of new polymers, catalysts, and pharmaceuticals. Why it is studied: The unique structure of norbornane has attracted significant research interest. Its rigid structure, strained ring system, and versatile reactivity make it an attractive target for synthetic chemists and materials scientists.'

Cross-References

ID SourceID
PubMed CID67510
MeSH IDM0133621

Synonyms (11)

Synonym
norsabinane
bicyclo[3.1.0]hexane
bicyclo(3.1.0)hexane
285-58-5
A18573
northujane
JAPMJSVZDUYFKL-UHFFFAOYSA-N
FT-0746494
SY274842
mfcd20486282
DTXSID20951186

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Compound 9 was also shown to be orally bioavailable and brain penetrable."( Heterocyclic modification of a novel bicyclo[3.1.0]hexane NPY1 receptor antagonist.
Antal-Zimanyi, I; Chen, L; Clarke, WJ; Hogan, JB; Hu, S; Huang, Y; Iben, LG; Luo, G; Mattson, G; Poindexter, GS; Russell, JW, 2013
)
0.39

Dosage Studied

ExcerptRelevanceReference
" Compound 9 demonstrated reduced spontaneous nocturnal food intake in a rat model when dosed ip."( Heterocyclic modification of a novel bicyclo[3.1.0]hexane NPY1 receptor antagonist.
Antal-Zimanyi, I; Chen, L; Clarke, WJ; Hogan, JB; Hu, S; Huang, Y; Iben, LG; Luo, G; Mattson, G; Poindexter, GS; Russell, JW, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.57)18.7374
1990's0 (0.00)18.2507
2000's16 (57.14)29.6817
2010's11 (39.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.18 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index5.32 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (93.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]